S&P May Pare Credit Ratings On Sanofi-Aventis

From Associated Press (September 7, 2010)


NEW YORK -- Standard & Poor’s Ratings Services may cut its credit ratings on Sanofi-Aventis, which is trying to buy the biotechnology company Genzyme.

The agency placed its ‘AA-’ long-term credit rating and ‘A-1+’ short-term rating on credit watch negative Tuesday, meaning that it may reduce them to reflect the debt that would come with buying out Genzyme Corp. It said that such a deal would reduce its credit standing at least through 2011.

The Paris drug maker offered $18.5 billion, or $69 per share, for Genzyme on Aug. 29. Genzyme rejected the offer the next day.

Standard & Poor’s placed Genzyme’s ratings on CreditWatch with positive implications.

Shares of Sanofi-Aventis SA dipped 39 cents to $29.81 in afternoon trading, while Genzyme stock rose 20 cents to $70.69.

 

Posted: September 2010


View comments

Hide
(web4)